Rheumatoid Arthritis Trial, Recruiting NCT03003572 Sponsor: Centre Hospitalier Universitaire de Saint Etienne Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT03003572
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with primary Sjögren's syndrome based on a specific set of internationally recognised diagnostic guidelines (called the American-European Consensus Criteria)
  • People who have been informed about the study and have signed the consent form agreeing to take part

Who may not be able to join:

  • People whose Sjögren's syndrome is caused by or linked to another condition (called secondary Sjögren's syndrome)
  • People who also have another systemic autoimmune disease, such as rheumatoid arthritis, a condition called ANCA-associated vasculitis, or mixed connective tissue disease
  • People who are unable to sign, or who do not wish to sign, the consent form
  • People who are unable to attend, or who do not wish to attend, the follow-up appointments required by the study
  • People who have been treated with certain medications — including abatacept, sifalimumab, rontalizumab, anifrolumab, belimumab, TNF blockers, or interferon — within the 6 months before joining the trial
  • People who currently have signs or symptoms of an active infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pascal CATHEBRAS, MD PhD, Centre Hospitalier Universitaire de Saint Etienne

Phone: (0)477828342

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Registry
ClinicalTrials.gov
Start date
27 March 2018
Est. completion
1 June 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Proportion of anti-Ro/SSA IgE positive patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov